| Autor: |
Abdullah M, Al-Rubaish, Fahad A, Al-Muhanna, Abdullah M, Alshehri, Abdulla A, Alsulaiman, Majed M, Alabdulali, Fahad, Alkhamis, Abdulallh S, Alamri, Rudaynah A, Alali, Mohammed S, Akhtar, Cyril, Cyrus, Daniel M F, Claassens, Folkert W, Asselbergs, Amein K, Al-Ali |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Drug metabolism and personalized therapyReferences. 37(1) |
| ISSN: |
2363-8915 |
| Popis: |
To mitigate the incidence of recurrent stroke in patients, dual antiplatelet therapy comprising aspirin and clopidogrel is usually administered. Clopidogrel is a prodrug and its bioactivation is catalyzed by cytochrome P450 (CYP)2C19. The main objective of this work was to determine the prevalence ofThis prospective (2018-2019) study was conducted on 256 patients (age 61 ± 12.5) clinically diagnosed with ischemic stroke who were genotyped using Spartan RXFrom the total patient group (256), upon admission, 210 patients were prescribed either aspirin, clopidogrel or dual antiplatelet therapy. Of the 27 patients with theThis study shows the suitability of using genotyping to guide antiplatelet therapy in ischemic stroke patients in a clinical setting. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
